Tech Company Financing Transactions
Aptatek BioSciences Funding Round
On 6/19/2024, Aptatek BioSciences secured financing from Canterbury Scientific, National PKU Alliance and private investors.
Transaction Overview
Company Name
Announced On
6/19/2024
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Canterbury Scientific (Lead Investor)
National PKU Alliance (Lead Investor)
Proceeds Purpose
The company intends to use the funds to complete clinical studies of its groundbreaking in-home monitoring platform for phenylketonuria (PKU).
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
303 College Rd E
Princeton, NJ 08540
USA
Princeton, NJ 08540
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Aptatek BioSciences, Inc., is developing game-changing home monitoring tools for chronic disease patients and medication management. The Aptatek system combines its proprietary aptamer assay approach with a handheld, smartphone-based test platform. The company has already received Breakthrough Device designation by the FDA, for its first product - a phenylketonuria (PKU) monitoring test.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Boyce-Jacino
Co-Founder
Milan Stojanovic
Co-Founder
Tilla Worgall
Browse more venture capital transactions:
Prev: 6/19/2024: Liquid Instruments venture capital transaction
Next: 6/19/2024: Decagon venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs